Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bruch membrane

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Bruch membrane. Displaying page 1 of 1.
    EudraCT Number: 2021-000434-34 Sponsor Protocol Number: UMCU-VASC-CO-003 Start Date*: 2023-04-12
    Sponsor Name:University Medical Centre Utrecht
    Full Title: A placebo-controlled, double-blind randomized trial evaluating the effect of etidronate in young patients with pseudoxanthoma elasticum on ectopic mineralization.
    Medical condition: Pseudoxanthoma elasticum
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003226-71 Sponsor Protocol Number: MR42410 Start Date*: 2022-01-31
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIB, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFECTIVENESS AND SAFETY OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB VS AFLIBERCEPT TREAT & ...
    Medical condition: Neovascular Age-Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FI (Completed) HU (Completed) DK (Completed) PT (Completed) GR (Completed) IE (Completed) NL (Completed) DE (Completed) AT (Completed) PL (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000986-30 Sponsor Protocol Number: 140109 Start Date*: 2015-03-03
    Sponsor Name:IRCCS Ospedale San Raffaele U.O. Oculistica
    Full Title: Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Angioid Streaks (EYLEA-STRIE)
    Medical condition: Choroidal neovascularization secondary to angioid streaks .
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001235-30 Sponsor Protocol Number: MSI-1256F-302 Start Date*: 2005-10-26
    Sponsor Name:Genaera Corporation
    Full Title: A Phase 3 Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Re...
    Medical condition: Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003883-28 Sponsor Protocol Number: SB15-3001 Start Date*: 2020-05-28
    Sponsor Name:Samsung Bioepis Co., Ltd.
    Full Title: A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB15 (proposed aflibercept biosimilar) and Eyl...
    Medical condition: Neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) HU (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003018-42 Sponsor Protocol Number: OPH1004 Start Date*: 2014-10-10
    Sponsor Name:OPHTHOTECH CORPORATION
    Full Title: A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination wi...
    Medical condition: Subfoveal neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    20.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) ES (Prematurely Ended) FI (Completed) NO (Completed) DE (Prematurely Ended) EE (Prematurely Ended) LV (Prematurely Ended) SK (Prematurely Ended) IT (Completed) AT (Prematurely Ended) HU (Completed) HR (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002997-33 Sponsor Protocol Number: OPH1002A Start Date*: 2014-02-11
    Sponsor Name:OPHTHOTECH CORPORATION
    Full Title: A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (anti PDGF-b pegylated aptamer) administered in combination w...
    Medical condition: Subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10071129 Neovascular age-related macular degeneration LLT
    16.1 100000004853 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) LV (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) EE (Prematurely Ended) SK (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004000-33 Sponsor Protocol Number: INZ701-201 Start Date*: 2021-06-10
    Sponsor Name:Inozyme Pharma, Inc.
    Full Title: A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period i...
    Medical condition: Treatment of patients with ABCC6 Deficiency Manifesting as Pseudoxanthoma elasticum (PXE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10037150 Pseudoxanthoma elasticum PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003017-18 Sponsor Protocol Number: OPH1003 Start Date*: 2013-11-21
    Sponsor Name:OPHTHOTECH CORPORATION
    Full Title: A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (anti PDGF-b pegylated aptamer) administered in combination w...
    Medical condition: Subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
    Disease: Version SOC Term Classification Code Term Level
    18.1 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    18.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Completed) ES (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001961-20 Sponsor Protocol Number: FYB201-C2015-01-P3 Start Date*: 2015-11-24
    Sponsor Name:Bioeq GmbH
    Full Title: Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (COLUMBUS-AMD)
    Medical condition: Subfoveal neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    20.0 100000116602 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) DE (Completed) HU (Completed) ES (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003320-36 Sponsor Protocol Number: 190342-038 Start Date*: 2015-03-02
    Sponsor Name:Allergan Limited
    Full Title: Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON Study)
    Medical condition: Geographic Atrophy Secondary to Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 16:11:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA